Oramed Pharmaceuticals Inc. (ORMP) Tops Q3 EPS by 19c

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) reported Q3 EPS of $0.15, $0.19 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.18 million.

For earnings history and earnings-related data on Oramed Pharmaceuticals Inc. (ORMP) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)